Promising early results show that longstanding Harvard Stem Cell Institute (HSCI) research may have paved the way for a breakthrough treatment of Type 1 diabetes. Utilizing research from the Melton Lab, Vertex Pharmaceuticals has developed VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes (T1D). In conjunction with immunosuppressive therapy, VX-880 produced robust restoration of islet cell function on Day 90 in the first patient in its Phase 1/2 clinical trial.... Read more about A new therapy for treating Type 1 diabetes
In June, the Harvard Stem Cell Institute (HSCI) co-sponsored the annual meeting of the International Society for Stem Cell Research. Held virtually for the first time, the conference brought together close to 4,000 scientists from 59 countries to discuss the latest in stem cell research.
David Scadden, co-director of HSCI, opened the conference by welcoming attendees and encouraging researchers to apply their expertise in stem cell science to the ongoing COVID-19 pandemic: “This has been a time of great crisis and upheaval that has really reminded us of the extraordinary power...
The 12th annual Business of Regenerative Medicine conference, hosted by the Harvard Stem Cell Institute on 15-16 July 2019, examined how to define and create “value” in a field set to transform human health.
Boston-area stem cell scientists convene to discuss regulation, future research directions, career paths
The Harvard Stem Cell Institute (HSCI) convened for its 14th annual retreat on May 21st at Harvard Medical School in the Joseph B. Martin Conference Center. The event was a mix of presentations and panels, with poster sessions and topic tables in the New Research Building’s sunny atrium and courtyard.
Around 300 HSCI scientists welcomed keynote speaker...
The Harvard Stem Cell Institute (HSCI) was launched in 2004 with the express goal of pursuing the promise of stem cell science. In April 2019 we celebrate our 15th anniversary, and reflect on how far we have come.
Collaboration across Harvard
Our founding document listed 28 participating Harvard faculty, including co-founders Doug Melton and David Scadden. By May 2004 that list had expanded to 39 faculty, and in 2005 the number had almost doubled.